15. **Lung MA.** Autonomic nervous control of myoepithelial cells and secretion in submandibular gland of anaesthetized dogs. *J Physiol* 2003;**546**:837–50.
16. **Hessel PA,** Mitchell I, Tough S, *et al.* Risk factors for death from asthma. Prairie Provinces Asthma Study Group. *Ann Allergy Asthma Immunol* 1999;**83**:362–8.
17. **Global Initiative for Asthma (GINA).** *Global strategy for asthma management and prevention.* GINA, 2007.
18. **James AL,** Green FH, Abramson MJ, *et al.* Airway basement membrane perimeter distensibility and airway smooth muscle area in asthma. *J Appl Physiol* 2008;**104**:1703–8.
19. **Mauad T,** Ferreira DS, Costa MB, *et al.* Characterization of autopsy-proven fatal asthma patients in Sao Paulo, Brazil. *Rev Panam Salud Publica* 2008;**23**:418–23.
20. **Sheehan JK,** Richardson PS, Fung DC, *et al.* Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. *Am J Respir Cell Mol Biol* 1995;**13**:748–56.
21. **Clueroe A,** Holloway L, Thomson K, *et al.* Bronchial gland duct ectasia in fatal bronchial asthma: association with interstitial emphysema. *J Clin Pathol* 1989;**42**:1026–31.
22. **Benayoun L,** Druilhe A, Dombret MC, *et al.* Airway structural alterations selectively associated with severe asthma. *Am J Respir Crit Care Med* 2003;**167**:1360–8.
23. **Sanchez-Mora N,** Rendon-Henao J, Monroy V, *et al.* Antigenic profile of human bronchial gland. *Histol Histopathol* 2005;**20**:865–70.
24. **Sato K.** Pharmacological responsiveness of the myoepithelium of the isolated human axillary apocrine sweat gland. *Br J Dermatol* 1980;**103**:235–43.
25. **Inglis SK,** Corboz MR, Taylor AE, *et al.* In situ visualization of bronchial submucosal glands and their secretory response to acetylcholine. *Am J Physiol* 1997;**272**:L203–10.
26. **Springer J,** Groneberg DA, Pregla R, *et al.* Inflammatory cells as source of tachykinin-induced mucus secretion in chronic bronchitis. *Regul Pept* 2005;**124**:195–201.
27. **Ballard ST,** Spadafora D. Fluid secretion by submucosal glands of the tracheobronchial airways. *Respir Physiol Neurobiol* 2007;**159**:271–7.
28. **Carroll NG,** Mutavdzic S, James AL. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. *Thorax* 2002;**57**:677–82.
29. **Gailit J,** Marchese MJ, Kew RR, *et al.* The differentiation and function of myofibroblasts is regulated by mast cell mediators. *J Invest Dermatol* 2001;**117**:1113–9.
30. **Gosens R,** Dueck G, Rector E, *et al.* Cooperative regulation of GSK-3 by muscarinic and PDGF receptors is associated with airway myocyte proliferation. *Am J Physiol Lung Cell Mol Physiol* 2007;**293**:L1348–58.
31. **Gosens R,** Zaagsma J, Meurs H, *et al.* Muscarinic receptor signaling in the pathophysiology of asthma and COPD. *Respir Res* 2006;**7**:73.
32. **James A,** Carroll N. Theoretic effects of mucus gland discharge on airway resistance in asthma. *Chest* 1995;**107**:110S.
33. **Chalmers GW,** MacLeod KJ, Thomson L, *et al.* Smoking and airway inflammation in patients with mild asthma. *Chest* 2001;**120**:1917–22.
34. **Schultz HD,** Davis B, Coleridge HM, *et al.* Cigarette smoke in lungs evokes reflex increase in tracheal submucosal gland secretion in dogs. *J Appl Physiol* 1991;**71**:900–9.
35. **Lewis DJ,** Jakins PR. Effect of tobacco smoke exposure on rat tracheal submucosal glands: an ultrastructural study. *Thorax* 1981;**36**:622–4.

Lung alert

Clinical characteristics of the H1N1 virus

Prior to 2005, human infections with classic swine influenza viruses were reported at a rate of only one or two cases per year. However, by the late 1990s multiple strains and subtypes (H1N1, H3N2 and H1N2) of triple-reassortant swine influenza A (H1) viruses containing genes from avian, human and swine influenza viruses had emerged and became enzootic among pig herds in North America.

In the first study, 11 sporadic cases of human infections with triple-reassortant swine influenza A (H1) occurring between December 2005 through February 2009 are described using information collected by the Centre for Disease Control in the USA. All but one of the cases definitely had exposure to pigs. Four patients had underlying medical conditions and the median age of the 11 infected was only 10 years. Symptoms included fever, cough, headache, sore throat, diarrhoea and myalgia. All patients recovered.

In the second study, between 15 April and 5 May 2009, a further 642 confirmed cases of H1N1 are described from 41 states in the USA. In this paper the age range is much broader (3 months to 81 years). However, the symptom profile is very similar and the spectrum of disease severity ranges from mild self-limiting illness to hospitalisation and death.

Both the studies provide a description of symptoms and outcomes of this evolving virus and emphasise the importance of communication and collaboration worldwide to better understand the disease. It is possible that H1N1 infection in humans presents the greatest pandemic threat since the emergence of influenza A (H3N2) virus in 1968. The continued identification of new cases worldwide indicates sustained human to human transmission with great epidemic and pandemic threat to global public health.

- Shinde V, Bridges CB, Uyeki TM, *et al.* Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. *N Engl J Med* 2009;**360**:2616–25.
- Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of novel swine-origin influenza A (H1N1) virus in humans. *N Engl J Med* 2009;**360**:2605–15.

S A Abbas

Correspondence to: Dr S A Abbas, Specialist Registrar, Llandough University Hospital, Vale of Glamorgan, UK; ali.abbas@doctors.org.uk

Thorax 2010;**65**:38. doi:10.1136/thx.2009.127399